Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

• Status: Recruiting
• Trial end date: 2025-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary Objective:

To determine whether amcenestrant per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer

Secondary Objectives:

• To compare the overall survival in the 2 treatment arms

• To assess the objective response rate in the 2 treatment arms

• To evaluate the disease control rate in the 2 treatment arms

• To evaluate the clinical benefit rate in the 2 treatment arms

• To evaluate the duration of response in the 2 treatment arms

• To evaluate the PFS according to the estrogen receptor 1 gene (ESR1) mutation status in the 2 treatment arms

• To evaluate the pharmacokinetics of amcenestrant as single agent

• To evaluate health related quality of life in the 2 treatment arms

• To compare the overall safety profile in the 2 treatment arms

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Anastrozole; Exemestane; Fulvestrant; Letrozole; Tamoxifen

Criteria

Inclusion criteria :

• 18 years or older.

• Histological or cytological diagnosis of adenocarcinoma of the breast.

• Locally advanced not amenable to radiation therapy or surgery in a curative intent, and/or metastatic disease.

• ER positive status.

• HER2 negative status.

• Participants must have received no more than 1 prior chemotherapeutic or 1 targeted therapy regimen for advanced/metastatic disease.

• In the main study, a prior treatment with a CDK 4/6 inhibitor is mandatory if this treatment is approved and can be reimbursed for this participant. The percentage of participants without previous CDK 4/6 inhibitor will be capped to 20%. In the Chinese extension cohort, previous treatment with a CDK 4/6 inhibitor will not be mandatory, and there will be no limitation to the number of participants naïve to CDK4/6 inhibitor.

• Participants must present a secondary endocrine resistance to endocrine therapy defined as: progression while on endocrine therapy after at least 6 months of treatment for advanced breast cancer, or relapse while on adjuvant endocrine therapy but after the first 2 years, or with a relapse within 12 months after completing adjuvant endocrine therapy.

• Male or Female.

Exclusion criteria:

• Eastern Cooperative Oncology Group performance status ≥2.

• Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of amcenestrant. Participants unable to swallow normally and to take capsules.

• Participant with any other cancer. Adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or any other cancer from which the participant has been disease free for >3 years are allowed.

• Severe uncontrolled systemic disease at screening .

• Participants with known brain metastases that are untreated, symptomatic or require therapy to control symptoms.

• Prior treatment with mammalian target of rapamycin inhibitors or any other selective estrogen receptor degrader (SERD) compound, except fulvestrant if stopped for at least 3 months before randomization.

• Treatment with drugs that have the potential to inhibit UGT less than 2 weeks before randomization.

• Treatment with strong CYP3A inducers within 2 weeks before randomization.

• Ongoing treatment with drugs that are substrate of P-glycoprotein (P gp) (dabigatran, digoxin, fexofenadine), or of Breast Cancer Resistance Protein (BCRP) (rosuvastatin, sulfasalazine).

• Treatment with anticancer agents (including investigational drugs) less than 3 weeks before randomization.

• Inadequate hematological, coagulation, renal and liver functions.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.